|
Bavarian to start Phase III prostate cancer vaccine
|
|
|
Posted on
Oct 07 2008 2:59 AM
by
adeal
|
Danish vaccine maker Bavarian Nordic (BAVA.CO: Quote, Profile, Research, Stock Buzz) said on Tuesday it would start a Phase III study in 2010 for its prostate cancer vaccine after the Phase II study data was positive. The Phase II data for the Prostvac vaccine showed statistically significant improved overall survival in a sample of 125 patients. Patients treated with the vaccine had a longer median overall survival by 8.5 months compared to the placebo group.
|
|
No comment found for this blog
|
|